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months) between an innovative product’s FDA and EMA approval. Average time to 
reimbursement in the EU5 after the EMA approval ranges from 7.0-11.2 months. 
Pharmaceutical companies need to plan ahead and submit the application dossier 
as early as possible to achieve faster access, especially for oncology products. Early 
access programmes, such as ATU in FRA and Cnn in ITA, may also be considered 
in certain countries.
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of tHe AmbUlAtory And HoSPitAl cAre ServiceS Among tHe mexicAn 
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Objectives: Health care utilization is likely to be conditioned to socioeconomic 
factors. The aim of this study is to identify the impact of these determinants, as 
well as the health perception variables in the use of the health services in the 
Mexican population. MethOds: Data from the National Health Survey 2012 was 
used to identify social, economic and health perception variables among users of 
the ambulatory and hospital care services. Statistical analysis was performed to 
test significant differences among users in relation to gender, equivalent household 
income and age data. A Probit model was used to identify and measure the impact 
of these variables on the utilization of the ambulatory care services among patients 
and a Poisson model for modelling the number of hospitalizations. Results: 8.48% 
of the population used ambulatory services during the last two weeks and 3.89% 
required hospitalization at least once during the last year. Significant statistical 
differences were observed between gender, income and age with the ambulatory 
and hospital care use. The results from the Probit model showed that men are less 
likely to use ambulatory services compared to women, as well as individuals at 
younger ages (0-9 years) (Z= 7.95). Additionally, at higher income deciles, a positive 
significant impact was found for using this service. The Poisson model revealed that 
education, employment and medical insurance are statistically significant variables 
with positive impact on the times people are hospitalized. Finally, other variables 
with a positive impact on both types of care are morbidity and the illness percep-
tion mainly when this is severe. cOnclusiOns: In addition to the influence of 
socioeconomic and demographic factors, health perceptions among patients are 
significant determinants that explain the decision and frequency of the health care 
utilization in the Mexican population.
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Objectives: Public expenditure on health on India is around 1% of GDP and 
79% expenditure in health of people is through out-of-pocket. Almost 30 % of the 
households slide into poverty due to high treatment costs and medicines. Though, 
India is considered as pharmacy for developing countries, yet due to poor regu-
latory control there is huge price variation in off-patent branded generics, even 
50 times or more and leaving affordability at the mercy of prescribers/dispens-
ers. MethOds: The Government of Rajasthan (a federal State in India with popu-
lation about 70 million) has launched a scheme called Chief Minister’s Free Drug 
Distribution Scheme (CMFDDS) for providing free essential medicines to all irre-
spective of their economic status through establishing an autonomous Rajasthan 
Medical Services Corporation (RMSC). By well-defined transparent prequalification 
measures for products and suppliers, RMSC procures quality medicines through 
cost-minimization. Educational, managerial and regulatory strategies have been 
used to promote compliance by stakeholders Results: Quality essential medi-
cines are procured at unbelievable low cost compared to market retail prices, e.g. 
procurement cost / market retail prices for strip of 10 tablets of DICLOFENAC 50 
mg, ATORVASTATIN 10 mg, GLIMEPIRIDE 2 mg, and CLOPIDOGREL 75 mg are INR 
1.24/31.73, 2.98/103.74, 1.95/125.00 and 8.54/147.44 respectively (1 USD= INR 63) 
resulting an increase in access and equity with monthly patient inflow increased 
from 44,000,00 to 66,000,000 and decrease/elimination in out of pocket expenditure, 
as amount spent on medicines in 2 years is around INR 5,070,000,000 whereas mar-
ket price of these medicines would be. INR 30,000,000,000. cOnclusiOns: Essential 
medicines are not costly but are being made expensive. By utilizing the pricing 
information of quality medicines along with transparent pooled procurement and 
proper distribution system can make free access to medicines, especially under-
served population with a strong political commitment coupled with the proper 
strategies in low resource settings.
PHP48
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Objectives: There is a growing need for the development of real-world clinical evi-
dences, particularly in the field of health technology assessments. The objective of 
this analysis was to identify and describe the key elements for the implementation 
of a program aiming to develop real-world clinical evidences in Quebec. MethOds: 
A literature review was conducted to analyze the position, progress and devel-
opment of strategies fostering risk management and development of real-world 
clinical evidences in different provinces and countries. A literature search was 
performed using electronic databases including Pubmed, Medline and Embase. 
Additional guidelines and government policies were retrieved using Google and 
Google Scholar. The following keywords, were used for search, alone or in combina-
tion: risk-sharing and product listing agreements, coverage with evidence devel-
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PreScriPtion clAimS dAtAbASeS
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Objectives: Prescription claims databases are commonly used for identifying 
patients for disease management programs, studying health outcomes and report-
ing on quality measures. A shortcoming of claims databases for these purposes is 
that they include only prescriptions that are adjudicated through insurance plans. 
Growth in the use of cash discount generic programs and the frequent use of drug 
samples suggests that an increasing number of prescriptions dispensed to insured 
consumers may not be captured on claims databases. We examined the extent to 
which prescription claims databases do not provide complete records of insured 
patients’ prescription drug use. MethOds: We used the 2009 Medical Expenditure 
Panel Survey (MEPS) dataset. We included participants who purchased at least one 
prescription medication and who had prescription drug insurance for all of 2009. We 
quantified the extent to which insured patients used drug samples, drugs paid for 
by cash only, and/or discount generics. We measured the numbers of prescriptions 
in each of these categories and the numbers of consumers who had at least one 
prescription in each category. We reported descriptive statistics. Results: A total of 
75.1% of the U.S. non-institutionalized civilian population was insured for prescrip-
tion drugs. Of the total number of prescriptions dispensed to insured consumers, at 
least 0.8% were drug samples and 23.3 % were paid for by cash, of which 11.3% were 
potentially discount generics. Additionally, 11.6 % of insured consumers received 
at least one sample medication, 68.0% paid for at least one of their prescribed 
medications by cash, of which 42.5% used at least one potential discount generic 
product. cOnclusiOns: Our results indicate that drug samples do not contribute 
substantially to the problem of missing prescription data on claims databases. On 
the other hand, substantial number of prescriptions, paid for by cash and discount 
generics, may be missing from these databases.
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Objectives: To compare adherence to prescribed medications between patients 
with differed and those with immediate reimbursement at the point of service 
among Quebecers (Canada) with private drug insurance. MethOds: A retrospec-
tive cohort was constructed by selecting patients aged 18-64 years with private 
drug insurance from the reMed database between March 2008 and December 2012. 
An algorithm was developed to assess the patient’s reimbursement modality, i.e. 
the drug cost covered by the insurance company is reimbursed immediately at the 
point of service (immediate reimbursement) or at a later time (differed reimburse-
ment). Adherence was measured with the proportion of days covered (PDC) over one 
year for new users of the five most dispensed classes of medications, i.e. statins, 
proton pump inhibitors, thyroid hormones, antidepressants, and antihypertensive 
medications. Linear regression models were used to estimate the adjusted mean 
difference of the PDC between the two groups for each drug class. Results: The 
cohort included 6,494 patients with immediate and 1,950 patients with differed 
drug reimbursement. More than 40% of patients were 35-49 years, 26% were men 
and 85% were past or non-smokers. The mean PDC was 79.9 % for patients with 
immediate reimbursement and 89.3 % for patients with differed reimbursement 
among new users of statins. Corresponding figures were 48.3% and 45.1% for new 
users of proton pump inhibitors, 84.7% and 84.8% for new users of thyroid hormones, 
67.1% and 66.8% for new users of antidepressants, and 68.4% and 73.5% for new 
users of antihypertensive medications. The results of the linear regression analyses 
showed no significant differences between patients with immediate and differed 
drug reimbursement. cOnclusiOns: Patient’s adherence was low for several drug 
classes but appeared to be unaffected by differed reimbursement. The short period 
of time between the purchase of the medication and the reimbursement by the 
insurer might explain the results.
HeAltH cAre USe & Policy StUdieS – equity & Access
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Objectives: The purpose of this study was to estimate the time difference between 
the FDA and EMA approvals, as well as time to reimbursement in the UK, GER, 
FRA, ESP and ITA after EMA approval. MethOds: 32 high-cost drugs that were 
approved by both the FDA and EMA in 2011-2013 were assessed. Two-thirds of the 
sample were oncology drugs; the remaining one third included drugs treating other 
specialty diseases. Out of 32 drugs, 17 have obtained reimbursement from all EU5 
countries. Time of reimbursement was defined as the date of publication of SMC 
guidelines in SCT, NICE Final Appraisal Determination in ENG, CT decision in FRA, 
G-BA decision in GER, AIFA decision in ITA and AEMPS decision in ESP. Results: 
The average time difference between the FDA and EMA approvals (USA-EU approval 
interval) was 5.9 months (standard deviation (SD) 5.2 months), similar to the median 
USA-EU approval interval (6 months). The average time to reimbursement after EMA 
approval varies from 211 days in SCT (SD 75.9 days) to 336 days in ESP (SD 203 days). 
On average, the USA-EU approval interval for oncology drugs was almost twice as 
long as for non-oncology drugs (7.0 vs. 3.8 months), but there was minimal differ-
ence in time to reimbursement for oncology versus non-oncology drugs in the EU5, 
except in ESP, where the reimbursement decision for non-oncology drugs was 112 
days faster than for oncology drugs. cOnclusiOns: There is still a long gap (5.9 
A18  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
empanelled with payers, clinicians, policy makers, health economists, and patient 
representatives. This study sought to identify trends in key advice and actionable 
information derived from HTAC meetings in North America, Europe, and Asia that 
influenced the development of pipeline products. MethOds: Between 2010 and 
2013, 16 HTAC meetings were conducted for 14 Sanofi products in preclinical, Phase 
I and Phase II research. Six to 12 months after completion of each meeting, Clinical 
Development Leads completed a 15 question survey to identify the impact of HTAC 
on their projects. The results were collected and analyzed to determine the overall 
impact of the HTAC meetings. Results: A total of 14 surveys were completed. 
Advice and actionable information consisted of suggestions on clinical study design 
(36%), need of additional Health Economics and Outcomes Research (HEOR) studies 
(20%), and insights regarding pricing & reimbursement (11%). Feedback from HTAC 
influenced leadership committee decision-making (14%). Respondents agreed that 
the HTAC enabled important interactions with global experts early in development; 
moreover, all suggested that additional time be allowed to prepare for HTAC meet-
ings. All Clinical Development Leads indicated they would return to HTAC and rec-
ommend it to a colleague. cOnclusiOns: The most frequent HTAC advice involved 
suggestions to improve clinical study design. HTAC also recommended performing 
additional HEOR studies. In many instances, feedback from HTAC influenced leader-
ship committee decision-making, such as licensing agreements.
HeAltH cAre USe & Policy StUdieS – Health care costs & management
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Objectives: Health care expenditure in the United States is expected to be 19.9% of 
GDP by 2022 and professional services account for a substantial portion of the total 
health care spending. The study aims to decompose the source of spending variation 
in professional services across Texas hospital referral regions (HRRs) due to quan-
tity, price, health risk and cost of doing business. MethOds: The study used 2011 
professional claims data for 3,829,083 members enrolled in Blue Cross Blue Shield 
(BCBS) of Texas, largest commercial insurance provider in Texas. Professional claims 
were classified into seven categories (i.e. evaluation and management, procedures, 
imaging, tests, durable medical equipment, other and exceptions/unclassified) using 
the Berenson-Eggers Type of Service (BETOS) code and Health Care Procedure Coding 
System (HCPCS) procedure codes. Geographic variation in spending per capita for 
each category was decomposed into quantity, price, cost of doing business and 
health risk. Results: Overall, spending variation in professional services is mainly 
explained by quantity (68.5%), followed by price (19.0%), cost of doing business (8.4%) 
and health risk (4.1%). Across categories, variation due to price was observed to be 
the highest for procedures (28.2%) and evaluation and management (22.4%) catego-
ries. Quantity accounted for majority of variation for imaging (80.5%), tests (83.2%), 
durable medical equipment (80.9%) and other (78.6%) categories. Contribution of 
health risk in explaining variation was relatively small for all professional subcate-
gories (range: 0.34% to 7.0%). cOnclusiOns: Majority of the geographic variation in 
professional services spending was explained by quantity. However, contribution of 
quantity and price varied considerably in explaining geographic differences across 
different professional services. Further exploration is required in understanding 
factors that lead to such variations across service types.
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Objectives: Reimbursement of brand drugs is typically set as a percentage of 
manufacturers’ listed prices. Thestudy evaluates trends the manufacturer listed 
prices at market entry of oral solid forms of new molecular entities (NMEs) approved 
by the US Food and Drug Administration (FDA) in the period 1990-2012. MethOds: 
Drug regulatory information derived from the FDA. Daily defined dosages (DDD) 
were collected from the World Health Organization. Average wholesaler prices 
(AWP) per unit at market entry derived from the RedBook. Prices were converted 
to 2013 dollars using the consumer price index. Descriptive statistics, 95% con-
fidence intervals and t-tests were performed in the analysis. Results: The FDA 
approved 576 NMEs during the study period; 505 were marketed as of Dec 31, 
2013, and 339 had a solid oral form at approval. The analysis included 243 NMES 
withcomplete DDD and price information. There were 141 NMEs approved in the 
1990s, 82 in the 2000s and 20 in the period 2000-2013. The average AWP per DDD 
was $13.81±$31.99 (95%CI:$8.53-$19.09) in the 1990s, $45.54±$92.44 (95%CI:$25.53-
$65.55) in the 2000s, and $112.83±$175.27 (95%CI:$36.02-$189.64) in the period 
2010-2013. The average AWP per DDD was significantly higher (p= 0.001) for FDA 
priority review drugs ($59.01±$113.90, 95%CI:$34.80-$83.23, n= 85) than for standard 
review drugs ($18.50±$52.38, 95%CI:$10.33 $26.66). It was also higher (p= 0.005) for 
orphan drugs ($88.64± $112.85, 95%CI: $43.49-$133.79, n= 24) than for non-orphan 
drugs ($26.54± $75.27, 95%CI: $16.57-$36.50). Last, the AWP was significantly higher 
(p< 0.001) for drugs marketed as of December 2013 ($34.75±$84.66, 95%CI: $23.66-
$45.84, n= 224) than for discontinued drugs ($8.15±$5.30, 95%CI: $5.76-$10.53, 
opment, patient access scheme, drug reimbursement, risk management, clinical 
evidence development, real-world, real-life setting. Results: A total of 15 programs 
of risk management and development of real-world clinical evidence were ana-
lyzed. Of these programs, 6 were selected as relevant models for the province of 
Quebec. For 4 of these programs, ongoing in Canada, Australia and Europe, it was 
the manufacturer’s responsibility to develop and perform data collection. Otherwise, 
it was the responsibility of government agencies. For 100% of analyzed programs, 
a substantial financial participation from the manufacturer was required. Half of 
programs reported a direct participation of academic research institutions in the 
collection and processing of data while the other half did not mention their partici-
pation explicitly. Fifty percent of these programs were related to a reimbursement 
decision. cOnclusiOns: This study indicated that the success of programs aiming 
to develop real-world clinical evidences involve active participation of academic 
research organizations as well as support from the manufacturers. These key ele-
ments should be considered in developing such a program in Quebec.
HeAltH cAre USe & Policy StUdieS – formulary development
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mAking: tHe cASe for ontArio
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Objectives: The Ontario Drug Benefit (ODB) Formulary is the publicly funded pro-
vincial drug plan in Ontario. Drugs are included subsequent to a review of submitted 
clinical efficacy and pharmacoeconomic evidence by the Committee to Evaluate 
Drugs (CED). The objective of this analysis was to examine the degree to which 
economic evidence was utilized to inform drug reimbursement decision making 
in Ontario. MethOds: All publicly available CED “Recommendation and Rationale” 
documents were reviewed to classify type of economic evidence, CED recommenda-
tions and rationales. Descriptiveand logistic regression analyses were conducted 
to examine the extent that economic evaluation impacts CED recommendations 
among other potential predictor factors. Results: A total of 123 separate recom-
mendations were retrieved (July 2007 to November 2012). Forty –seven percent 
received a fund recommendation while 53% received a do not fund recommenda-
tion. Almost all recommendations included some discussion of economic evidence; 
however complexity was limited to a discussion of price of therapy only for the 
majority (70%). Regression analysis found that documents including a discussion 
of economic evidence beyond price and statement of a price of therapy less than 
or similar to alternatives were more likely to result in positive recommendations 
(p < 0.05). cOnclusiOns: Although economic evidence was routinely reviewed, 
discussion was usually limited to price of therapy. However, when pharmacoeco-
nomic evidence beyond price alone was discussed, a recommendation to fund by 
the CED was more likely.
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AcAdemy of mAnAged cAre PHArmAcy (AmcP) doSSierS: USe in HeAltH 
cAre deciSion mAking
Hogue S.1, Brogan A.1, Earnshaw S.2, Khan S.1, Nelsen S.1
1RTI-Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Research Triangle 
Park, NC, USA
Objectives: The Academy of Managed Care Pharmacy (AMCP) dossier format was 
introduced in 2000 to guide manufacturers in presenting evidence for new pharma-
ceuticals, biologics, and vaccines to gain reimbursement and/or formulary place-
ment in the United States (US) health care system. Limited information has been 
published on the role of these dossiers in health care decision making; therefore, 
this study aimed to characterize decision makers’ use of AMCP dossiers in access 
and formulary placement for new health technologies. MethOds: We reviewed the 
published literature and third-party websites to identify how health care decision 
makers employ AMCP dossiers. We then developed a discussion guide for use in 
one-on-one interviews with medical and pharmacy directors involved in formulary 
decision making at a range of US health plans (national, regional, integrated). These 
interviews focused on how AMCP dossiers inform decision making and the useful-
ness of each dossier section. Results: Decision makers’ reports of the utility of 
AMCP dossiers varied greatly. Some decision makers use AMCP dossiers directly; 
others conduct research independent of the dossier. Pharmacy directors are more 
likely to use AMCP dossiers than medical directors, who typically are provided with 
briefs based partly on AMCP dossiers. Clinical study data, comparator information, 
and drug price are key in decision making. Decision makers are highly skeptical 
of AMCP dossier modeling sections and offered several suggestions to increase 
transparency and accountability. Great value is placed on succinctness and informa-
tion relevant to the disease area (e.g., in less-prevalent diseases). cOnclusiOns: 
Although there are formal guidelines for AMCP dossiers, health care decision mak-
ers seek information tailored to the disease and technology. Given the varied use of 
AMCP dossiers in practice and the reality of US health care reform, clearly under-
standing payer use and perspectives is important. Brevity and accuracy are crucial 
for health care decision making.
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Objectives: The research and development strategy for a new drug or device 
should be examined early in its clinical development to ensure that it ultimately 
delivers value for the patient, prescriber, and payer. The target product profile, clini-
cal study program, and value proposition for investigational products at Sanofi 
are evaluated regularly by an external Health Technology Advisory Council (HTAC) 
